Publications by authors named "Jason A Murray"
Article Synopsis
- Rifampin-resistant tuberculosis is a major global health issue, with treatment initiation rates low and often poor outcomes; a 6-month BPaL regimen shows high efficacy but initial high doses of linezolid led to significant side effects.
- Data collected from patients treated with BPaL between October 2019 and April 2022 revealed that 97.1% completed treatment, with only a small percentage experiencing relapse or significant adverse effects, largely due to careful dose adjustments of linezolid.
- The study concludes that the BPaL regimen, especially with individualized linezolid dosing and monitoring, has significantly improved treatment for rifampin-resistant tuberculosis, allowing for shorter treatment durations compared to past guidelines.
Background: Loeys-Dietz syndrome (LDS) is a rare autosomal-dominant connective tissue disorder caused by genetic mutations in the transforming growth factor-β (TGFβ) signaling pathway. In addition to vascular malformations, patients with LDS commonly present with bone and tendon abnormalities, including joint laxity. While TGFβ signaling dysregulation has been implicated in many of these clinical manifestations, the degree to which it influences the tendinopathy and tendon healing issues in LDS has not been determined.
View Article and Find Full Text PDF